ArticleRegenerative therapy2025
Salvianolic acid A facilitates cartilage repair in knee osteoarthritis model rats by promoting WDR5 expression.
Article in Regenerative therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Network Pharmacological Prediction and Experimental Analyses Reveal That Naringin Alleviates Osteoarthritis Progression by Targeting MMP13.Physiological research · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The aim of this study was to investigate the regulation of Salvianolic acid A (SAA) on the chondrogenic differentiation of bone mesenchymal stem cells (BMSCs), and its effect on cartilage repair in knee osteoarthritis (KOA) model rats and the action mechanism. Methods: Immunohistochemistry was performed to detect collagen type II (COL2A1), MMP13 and caspase-3 (CASP3) expression in cartilage tissues, and Safranin-O/Fast Green staining for cartilage damage. Alcian blue staining was performed to measure chondrogenic differentiation of BMSCs. Chondrocyte apoptosis was detected by using flow cytometry. Results: SAA treatment significantly attenuated cartilage damage in KOA model rats in a dose-dependent manner, and inhibited chondrocyte apoptosis induced by IL-1β in a dose-dependent manner. Moreover, SAA treatment promoted chondrogenesis-related proteins (COL2A1 and Aggrecan) expression and inhibited catabolism-related proteins (MMP13 and MMP3) expression both in the cartilage tissues from KOA model rat and in the IL-1β-treated chondrocytes. WD repeat domain 5 (WDR5) was a downstream target of SAA, and it facilitated chondrogenic differentiation of BMSCs derived from KOA model rats (KOA-BMSCs). Importantly, the inhibition of SAA treatment to the apoptosis and catabolism of chondrocyte and the promotion of SAA treatment to chondrogenic differentiation of KOA-BMSCs were rescued by silencing WDR5. Conclusion: Overall, SAA treatment could facilitate cartilage repair via inhibiting the apoptosis and catabolism of chondrocyte and promoting chondrogenic differentiation of KOA-BMSCs by promoting WDR5 expression. Our data suggested that SAA may a potential drug for the treatment of KOA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.